Novel Therapeutic Strategies for Managing BPH Progression

European Urology, Supplement

Volumn 2, Issue 8, 2003, Pages 20-26

  Djavan, B ^a   Barkin, J ^b  

^a UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

BPH; Combination therapy; Doxazosin; Dutasteride; MTOPS; Tamsulosin

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; DUTASTERIDE; STEROID 5ALPHA REDUCTASE INHIBITOR; TAMSULOSIN;

ABDOMINAL DISTENSION; CLINICAL TRIAL; CONFERENCE PAPER; DISEASE SEVERITY; DRUG EFFICACY; DYSPEPSIA; DYSURIA; EJACULATION DISORDER; FATIGUE; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; IMPOTENCE; LIBIDO DISORDER; MALAISE; MICTURITION DISORDER; NOCTURIA; PAIN; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; SIDE EFFECT; SYMPTOMATOLOGY; TREATMENT OUTCOME; URINARY FREQUENCY; VERTIGO;

EID: 0345308343     PISSN: 15699056     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eursup.2003.09.011     Document Type: Conference Paper

References (27)

1. Berry SJ, Coffey DS, Walsh PC, Ewing LL. The development of human benign prostatic hyperplasia with age. J Urol 1984;132: 474-9.
2. Jacobsen SJ, Girman CJ, Guess HA, Oesterling JE, Lieber MM. New diagnostic and treatment guidelines for benign prostatic hyperplasia. Potential impact in the United States. Arch Intern Med 1995;155: 477-81.
3. Djavan B, Marberger M. A meta-analysis on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction. Eur Urol 1999;36:1-13.
4. Jardin A. Future prospects for uroselective alpha-1-antagonists. Eur Urol 1999;36(Suppl 1):64.
5. Lepor H. Long-term efficacy and safety of terazosin in patients with benign prostatic hyperplasia. Terazosin Research Group. Urology 1995;45:406-13.
6. Lepor H, Kaplan SA, Klimberg I, Mobley DF, Fawzy A, Gaffney M, et al. Doxazosin for benign prostatic hyperplasia: long-term efficacy and safety in hypertensive and normotensive patients. The Multicenter Study Group. J Urol 1997;157:525-30.
7. Lukacs B, Grange JC, McCarthy C, Comet D. Clinical uroselectivity: a 3-year follow-up in general practice. BPH Group in General Practice. Eur Urol 1998;33(Suppl 2):28-33.
8. Lepor H. Phase III multicenter placebo-controlled study of tamsulosin in benign prostatic hyperplasia. Tamsulosin Investigator Group. Urology 1998;51:892-900.
9. Schulman CC, Cortvriend J, Jonas U, Lock TM, Vaage S, Speakman MJ. Tamsulosin: 3-year long-term efficacy and safety in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction: analysis of a European, multinational, multicenter, open-label study. Eur Urol 1999;36:609-20.
10. Narayan P, Lepor H. Long-term open-label, phase III multicenter study of tamsulosin in benign prostatic hyperplasia. Urology 2001; 57:466-70.
11. Schulman CC. Long-term aspects of medical treatment of BPH. Eur Urol 2001;40(Suppl 3):8-12.
12. Bramson HN, Hermann D, Batchelor KW, Lee FW, James MK, Frye SV. Unique preclinical characteristics of GG745, a potent dual inhibitor of 5AR. J Pharmacol Exp Ther 1997;282:1496-502.
13. Span PN, Voller MC, Smals AG, Sweep FG, Schalken JA, Feneley MR, et al. Selectivity of finasteride as an in vivo inhibitor of 5alpha-reductase isoenzyme activity in the human prostate. J Urol 1999;161: 332-7.
14. Roehrborn CG, Andriole G, Schalken JA, Wilson T, Clark RV. Dutasteride, a novel 5α-reductase inhibitor, reduces serum DHT to a greater extent versus finasteride and achieves finasteride's maximal reduction in a larger proportion of patients. Eur Urol Suppl 2003; 2(1):161 [Abstract 635].
15. O'Leary MP, Roehrborn C, Andriole G, Nickel JC, Boyle P, Höfner K. Improvements in benign prostatic hyperplasia-specific quality of life with dutasteride, the novel dual 5α-reductase inhibitor. BJU Int 2003;92:262-6.
16. Roehrborn CG, Boyle P, Nickel JC, Hoefner K, Andriole G. Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology 2002;60:434-41.
17. McConnell JD, Bruskewitz R, Walsh P, Andriole G, Lieber M, Holtgrewe HL, et al. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group. N Engl J Med 1998;338:557-63.
18. Boyle P, Roehrborn C, Andriole G, Nickel JC, Hofner K, O'Leary M. The impact of dutasteride, a novel 5α-reductase inhibitor, on the hallmarks of BPH progression and outcomes. Eur Urol Suppl 2002; 1(1): 107 [Abstract 418].
19. Boyle P, Gould AL, Roehrborn CG. Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride: meta-analysis of randomized clinical trials. Urology 1996;48: 398-405.
20. Roehrborn CG, Boyle P, Bergner D, Gray T, Gittelman M, Shown T, et al. for the PLESS Study Group. Serum prostate-specific antigen and prostate volume predict long-term changes in symptoms and flow rate: results of a four-year, randomized trial comparing finasteride and placebo. Urology 1999;54:662-9.
21. McConnell JD for the MTOPS Steering Committee. The long term effects of medical therapy on the progression of BPH: results from the MTOPS trial. J Urol 2002;167 [Abstract 1042].
22. Barkin J, Guimarães M, Jacobi G, Pushkar D, Taylor S, van Vierssen Trip OB, on behalf of the SMART-1 Investigator Group. Alpha-blocker therapy can be withdrawn in the majority of men following initial combination therapy with the dual 5α-reductase inhibitor dutasteride. Eur Urol 2003;44:461-6.
23. 1A-adrenoceptor antagonist: a meta-analysis of two randomised, placebo-controlled, multicentre studies in patients with benign prostatic obstruction (symptomatic BPH). Eur Urol 1996;29:155-67.
24. Coltman CAJ, Thompson IMJ, Feigl P. Prostate Cancer Prevention Trial (PCPT) update. Eur Urol 1999;35:544-7.
25. Tsukamoto S, Akaza H, Imada S, Koiso K, Shirai T, Ideyama Y, et al. Chemoprevention of rat prostate carcinogenesis by use of finasteride or casodex. J Natl Cancer Inst 1995;87:842-3.
26. Tsukamoto S, Akaza H, Onazowa M, Shirai T, Ideyama Y. A five-alpha-reductase inhibitor or an antiandrogen prevents the progression of microscopic prostate carcinoma to macroscopic carcinoma in rats. Cancer 1998;82:531-7.
27. Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003;349(3):215-24.